NDC 76310-024-15 - Foscavir
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 76310-024
- Requested NDC
- 76310-024-15
- Package NDCs from labels
- 76310-024-15, 76310-024-25, 76310-024-11, 76310-024-01, 76310-024-41, 76310-024-45
- Manufacturer
- Clinigen Limited
- Effective date
- 2025-12-11
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Foscavir - Clinigen Limited | Clinigen Limited | 2025-12-11 | HUMAN PRESCRIPTION DRUG LABEL |
| Foscavir - Clinigen Limited | Clinigen Limited | 2025-12-11 | HUMAN PRESCRIPTION DRUG LABEL |
| Foscavir - Clinigen Limited | Clinigen Limited | 2023-11-02 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 76310-024-15 | Foscavir | 1 in 1 CARTON | INJECTION, SOLUTION | 1 | 22 | |
| 76310-024-15 | Foscavir | 250 mL in 1 BOTTLE | INJECTION, SOLUTION | 250 | 22 | |
| 76310-024-25 | Foscavir | 10 in 1 CARTON | INJECTION, SOLUTION | 10 | 22 | |
| 76310-024-01 | Foscavir | 10 in 1 CARTON | INJECTION, SOLUTION | 10 | 16 | |
| 76310-024-11 | Foscavir | 1 in 1 CARTON | INJECTION, SOLUTION | 1 | 16 | |
| 76310-024-11 | Foscavir | 250 mL in 1 BOTTLE | INJECTION, SOLUTION | 250 | 16 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 76310-024 | FOSCAVIR (FOSCARNET SODIUM) INJECTION, SOLUTION [CLINIGEN LIMITED] | 21 | Current NDC, Legacy NDC, 3 package rows | 20241122_a09299d5-9c55-4cef-aed0-3a6a45532289.zip |
| 76310-024 | FOSCAVIR (FOSCARNET SODIUM) INJECTION, SOLUTION [CLINIGEN LIMITED] | 15 | Current NDC, Legacy NDC, 3 package rows | 20241122_90e3da4e-3b1f-428b-99ca-e4bed1c80028.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 76310-024-01 | ML - Milliliter | 76310-024 | d42ef6be-3360-41b4-979d-2ed71db24493 | 1 | 2015-03-03 |
| 76310-024-11 | ML - Milliliter | 76310-024 | e864fc20-812d-4db6-bf3d-ae61ddc14434 | 1 | 2019-05-02 |
| 76310-024-15 | ML - Milliliter | 76310-024 | c6522f73-3765-465b-8ae0-02b16a63fe2c | 1 | 2018-08-13 |
| 76310-024-25 | ML - Milliliter | 76310-024 | 97ab2e67-b14b-45cf-9c0f-a1eb895f75aa | 1 | 2013-02-13 |
| 76310-024-41 | ML - Milliliter | 76310-024 | 76dcf366-1dee-4a3b-8b56-8b106690bb42 | 1 | 2021-05-05 |
| 76310-024-45 | ML - Milliliter | 76310-024 | f43f7d6d-fa25-4dec-ab95-c3467b5d4590 | 1 | 2021-04-08 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| foscarnet sodium | ACTIVE INGREDIENT | 964YS0OOG1 | FOSCAVIR (FOSCARNET SODIUM) INJECTION, SOLUTION [CLINIGEN HEALTHCARE LTD.] | 8 | |
| foscarnet | ACTIVE MOIETY | 364P9RVW4X | FOSCAVIR (FOSCARNET SODIUM) INJECTION, SOLUTION [CLINIGEN HEALTHCARE LTD.] | 8 | |
| hydrochloric acid | INACTIVE INGREDIENT | QTT17582CB | FOSCAVIR (FOSCARNET SODIUM) INJECTION, SOLUTION [CLINIGEN HEALTHCARE LTD.] | 8 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | FOSCAVIR (FOSCARNET SODIUM) INJECTION, SOLUTION [CLINIGEN HEALTHCARE LTD.] | 8 | |
| foscarnet sodium | ACTIVE INGREDIENT | 964YS0OOG1 | FOSCAVIR (FOSCARNET SODIUM) INJECTION, SOLUTION [CLINIGEN HEALTHCARE LTD.] | 2 | |
| foscarnet | ACTIVE MOIETY | 364P9RVW4X | FOSCAVIR (FOSCARNET SODIUM) INJECTION, SOLUTION [CLINIGEN HEALTHCARE LTD.] | 2 | |
| hydrochloric acid | INACTIVE INGREDIENT | QTT17582CB | FOSCAVIR (FOSCARNET SODIUM) INJECTION, SOLUTION [CLINIGEN HEALTHCARE LTD.] | 2 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | FOSCAVIR (FOSCARNET SODIUM) INJECTION, SOLUTION [CLINIGEN HEALTHCARE LTD.] | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Anubis Barcelona Regul Oil | CETEARYL ETHYLHEXANOATE, PROPYLENE GLYCOL, GLYCERYL STEARATE SE | ANUBIS COSMETICS SL | eb68c3ab-7835-1a1c-e053-2995a90a0d66 | 2023-09-01 | Warnings | 059QF0KO0R |
| Anubis Barcelona | PROPANEDIOL, GLYCERIN, MAGNESIUM ASCORBYL PHOSPHATE | ANUBIS COSMETICS SL | eb53cba1-0509-43bc-e053-2995a90a5e09 | 2023-09-01 | Warnings | 059QF0KO0R |
| Anubis Barcelona Spa Line | ORYZA SATIVA (RICE) STARCH, PERLITE, PALMITIC ACID | ANUBIS COSMETICS SL | eb01a962-ab38-18ec-e053-2995a90acdeb | 2023-09-01 | Warnings | 059QF0KO0R |
| Anubis Barcelona | FERULIC ACID, VITAMIN C, DMAE | ANUBIS COSMETICS SL | eaf0770c-795d-0232-e053-2a95a90ae0b5 | 2023-09-01 | Warnings | 059QF0KO0R |
| Anubis Barcelona Regul OIl | PEG-40 HYDROGENATED CASTOR OIL, PROPYLENE GLYCOL, ARCTIUM MAJUS ROOT EXTRACT | ANUBIS COSMETICS SL | eb905bd0-c600-b8b2-e053-2995a90ad259 | 2023-09-01 | Warnings | 059QF0KO0R |
| Anubis Barcelona Regul Oil | PROPYLENE GLYCOL, GLYCERYL STEARATE SE, HUMULUS LUPULUS (HOPS) CONE EXTRACT | ANUBIS COSMETICS SL | eb7c418b-8bee-26a3-e053-2a95a90a4e96 | 2023-09-01 | Warnings | 059QF0KO0R |
| Anubis Barcelona Total Hydrating | BETAINE, GLYCERIN, POLYSORBATE 20 | ANUBIS COSMETICS SL | eaefe3b9-9064-18b1-e053-2a95a90a5765 | 2023-09-01 | Warnings | 059QF0KO0R |
| Anubis Barcelona New Even | LACTIC ACID, CITRIC ACID, GLYCOLIC ACID | ANUBIS COSMETICS SL | eaeeb6e0-5322-20c4-e053-2995a90a9fd9 | 2023-09-01 | Warnings | 059QF0KO0R |
| Anubis Barcelona Vital Line | HYDROLYZED COLLAGEN | ANUBIS COSMETICS SL | f564bbf0-3b5c-4a81-e053-2a95a90a7ea6 | 2023-08-29 | Warnings | 059QF0KO0R |
| FOSCARNET SODIUM | FOSCARNET SODIUM | Baxter Healthcare Corporation | 8a7caffd-9d8a-4d45-ad48-70d511a89c29 | 2023-08-28 | Boxed warning, Warnings, Adverse reactions | 1734377 964YS0OOG1 |
| REFL HS | ADENOSINUM TRIPHOSPHORICUM DINATRUM, NADIDUM, ARGENTUM NITRICUM, IPECACUANHA, ROBINIA PSEUDOACACIA, SULPHUR, ORIGANUM VULGARE, DUODENUM (SUIS), ESOPHAGUS (SUIS), FUNICULUS UMBILICALIS SUIS, STOMACH (SUIS), NUX VOMICA, COUMARINUM, ERYTHRAEA CENTAURIUM, PANCREATINUM, MURIATICUM ACIDUM, CITRICUM ACIDUM, FORMICUM ACIDUM, SARCOLACTICUM ACIDUM, COENZYME A, PROTEUS (MORGANI) | Deseret Biologicals, Inc. | 2fe2d3c1-1829-4a33-be8e-2bad52546f36 | 2023-07-17 | Warnings | QTT17582CB |
| Bacteriostatic Water | WATER | Medical Purchasing Solutions, LLC | 69485218-9343-952d-e053-2a91aa0ad4e8 | 2023-05-22 | Warnings, Adverse reactions | 059QF0KO0R |
| Sterile Water | STERILE WATER | Hikma Pharmaceuticals USA Inc. | b20a28b0-7dfa-42eb-9177-ec256d5a5ef7 | 2023-05-08 | Warnings, Adverse reactions | 059QF0KO0R |
| Sterile Water | WATER | Civica, Inc. | 3f49eedf-5bf5-4a95-b704-c956d860ca04 | 2023-04-07 | Warnings, Adverse reactions | 059QF0KO0R |
| Treprostinil | TREPROSTINIL | Sandoz Inc | 473297ca-a872-4052-a053-87dc8f0d3c13 | 2023-04-06 | Warnings, Adverse reactions | 059QF0KO0R |
| NOVOLOG | INSULIN ASPART | Novo Nordisk | 3a1e73a2-3009-40d0-876c-b4cb2be56fc5 | 2023-02-28 | Warnings, Adverse reactions | 059QF0KO0R |
| Acidum Muriaticum | ACIDUM MURIATICUM | Hahnemann Laboratories, INC. | f2aad04c-5151-6cab-e053-2a95a90ad3a7 | 2023-01-19 | QTT17582CB | |
| Rehydrate | AVENA SATIVA, EQUISETUM HYEMALE, HYPERICUM PERFORATUM, ULMUS FULVA, GLYCYRRHIZA GLABRA, SILICEA, PUERARIA LOBATA, CARLSBAD AQUA, ADENOSINUM TRIPHOSPHORICUM DINATRUM, GERMANIUM SESQUIOXIDE, HYDROGEN, OXYGEN, WIESBADEN | ParaDocs All Natural, Inc. | 648fab10-c46b-420f-a42c-6642009d83fb | 2023-01-10 | Warnings | 059QF0KO0R |
| Sterile Water | WATER | Fresenius Kabi USA, LLC | b45e9f1d-9c48-4b46-8541-d846b89540df | 2022-10-26 | Warnings, Adverse reactions | 059QF0KO0R |
| Eye wash | PURIFIED WATER | McKesson | bd089fde-24ba-4de5-e053-2995a90a39bb | 2022-10-18 | Warnings | 059QF0KO0R |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.